Navigation Links
New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients
Date:6/9/2009

Anti-TNF Experienced Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication or Reason for Discontinuation

COPENHAGEN, June 9 /PRNewswire/ -- A new analysis demonstrated that a greater proportion of patients with moderately to severely active rheumatoid arthritis (RA) who had prior treatment with anti-tumor necrosis factor (TNF)-alpha agents and received subcutaneous injections of SIMPONI(TM) (golimumab) once every four weeks experienced significant improvements in signs and symptoms through week 24, compared with patients receiving placebo. Patients continued to receive stable doses of methotrexate, sulfasalazine and/or hydroxychloroquine if receiving them at baseline. These data were presented at the 2009 European League Against Rheumatism (EULAR) Annual Congress.

Findings from the GOlimumab After Former anti-TNF Therapy Evaluated in RA (GO-AFTER) study, demonstrated that patients previously treated with adalimumab, etanercept or infliximab responded to and tolerated SIMPONI regardless of the type of prior anti-TNF therapy, as well as the number of prior therapies or reason for discontinuation. According to the study, 39 percent of patients receiving SIMPONI whose prior anti-TNF-alpha therapy had been discontinued due to a lack of efficacy achieved at least a 20 percent improvement in arthritis symptoms (ACR 20) at week 14, compared with 18 percent of patients receiving placebo (p<0.001). Thirty-four percent of patients receiving SIMPONI whose prior anti-TNF-alpha therapy had been discontinued for all other reasons achieved ACR 20, compared with 20 percent of patients receiving placebo (p=0.027).

"Golimumab has shown promise in the treatment of rheumatoid arthritis patients who have previously discontinued other anti-TNF-alpha therapies," said Josef S. Smolen, MD, Professor and Chairman, Departm
'/>"/>

SOURCE Centocor Ortho Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Meta-Analysis of Clinical Data Showed No Increased Risk of Cardiovascular Events Associated With Exenatide Use: Data Presented at ADA 2009
2. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
3. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(R) Stent System More Cost Effective Than Bypass Surgery in Patients With Complex Coronary Artery Disease
4. New MADIT II Clinical Data Analysis Shows Long-Term Survival Benefit for Implantable Defibrillator Therapy
5. New Analysis Evaluated Impact of Genetic Variation on Response to Prasugrel
6. New Imaging Analysis Predicts Brain Tumor Survival
7. Glycotex Investigational Compound GLYC-101 Achieves Accelerated Wound Closure Based on Interim Analysis
8. CRESTOR(R) Reduced CV Risk in Patients Achieving Low LDL and hsCRP Targets in New JUPITER Analysis
9. SYNTAX Analysis Finds Treatment With TAXUS(R) Express2(TM) Stents More Cost Effective Than Bypass Surgery in Many Patients With Complex Coronary Artery Disease
10. CDC Analysis Finds Unique Social and Behavior Intervention Helps Reduce MRSA Rates Up to 62% in Study Hospitals
11. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... June 20, 2013 Today Moscamed made ... launch of a new programme to control the dengue mosquito ... the State of Bahia. In previous trials Moscamed ... to rapidly reduce the number of dengue mosquitoes in a ... of these mosquitoes were reduced by 96% within 6 months ...
(Date:6/19/2013)... Calif. , June 19, 2013 Pharmacyclics, ... announced that The New England Journal of Medicine ... 2 study evaluating the investigational oral Bruton,s tyrosine kinase ... lymphoma (MCL) online. These data suggested ibrutinib may be ... Results of a separate study examining ...
(Date:6/19/2013)... , June 19, 2013  Haemonetics Corporation ... important developments in the pursuit of its previously ... http://photos.prnewswire.com/prnh/20120206/NE47232LOGO ) , Haemonetics has ... for the future production of medical devices currently ... is a leading global provider of integrated manufacturing ...
Breaking Medicine Technology:Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 2Moscamed Launches Urban Scale Project Using Oxitec GM Mosquitoes in Battle Against Dengue 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 2Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 3Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 4Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 5Ibrutinib Phase 2 Study Results in Patients with Mantle Cell Lymphoma Published in The New England Journal of Medicine 6Haemonetics Announces Next Steps in Manufacturing Transformation 2Haemonetics Announces Next Steps in Manufacturing Transformation 3Haemonetics Announces Next Steps in Manufacturing Transformation 4
(Date:6/19/2013)... As warmer weather arrives and vacations begin, Asheville’s ... summertime packages. , “Whether guests are traveling to Asheville ... staycation, we think that these available packages will offer ... so beautiful in the summertime and there is a ... can choose from, based on their interests, offers something ...
(Date:6/19/2013)... Across the globe billions of people ... to the medical advances that benefit developed western society. ... care and the necessary aid to help curb the ... Outlook with Ben Kingsley is partnering with ... which these people live and highlight the invaluable resources ...
(Date:6/19/2013)... Researchers from the Icahn School ... studies at ENDO 2013, The Endocrine Society’s Annual ... San Francisco.     , Mount Sinai researchers showed new data ... prostastic acid phosphatase (PAP) in Prostate Cancer (PCa) bone ... gland; revealed the prevalence of primary aldosteronism (PA) in ...
(Date:6/19/2013)... PrettySkin4Less announces it is stocking up ... by top skin care manufacturer EMINENCE to meet customer ... minerals and active organic ingredients to promote actual change ... beauty products offer. For this reason it’s not hard ... "I like products that do what they say they ...
(Date:6/19/2013)... Brain not working? Functional medicine pioneer Datis ... minor brain problems as brain fog, memory loss, fatigue, ... indicate the brain may be degenerating—or aging—too quickly, raising ... and other neurological diseases. Why Isn’t My Brain ... is now available online at Amazon and ...
Breaking Medicine News(10 mins):Health News:Fun Depot Partners with Brookstone Lodge on Summer Packages 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 2Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 3Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 4Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 5Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 6Health News:Diabetes Patients That Bring Glucose Meters to Doctor Visits Have Better Control Over Their Disease 7Health News:PrettySkin4Less Launches New Innovative Skin Serums with Active Organic Ingredients to World Wide Consumer Base 2Health News:Brain Not Working? Minor Symptoms Now Could Mean MS, Alzheimer's, or Parkinson's Later 2Health News:Brain Not Working? Minor Symptoms Now Could Mean MS, Alzheimer's, or Parkinson's Later 3
... - To gauge the efficacy of food labels and ... the Vanderbilt University for Health Services //embarked on a ... despite the enduring habit of reading food-labels, as a ... assimilate the information. The pointers that consumers often check ...
... California in Los Angeles reveals that in general, doctors give ... take the medication properly. // ,“This is a good ... patients and doctors,” said the lead author Derjung M. Tarn., ... the journal Archives of Internal Medicine. ,In order ...
... trials of a new vaccine against childhood ear and sinus ... ,According to the researchers, the vaccine will aim at ... that are life saving. ,"We are now in ... better," said Dr. Michael Pichichero, a professor of microbiology, immunology, ...
... The Cape Times has reported that illegal medicines are ... sold on the streets//. The report said many medicines ... the country's health department said the industry had grown ... close down the market because it's too large. So ...
... poll yesterday to see if parents supported the proposal to ... received 1,000 votes in support//. ,"Ofcom has ... junk food advertising would be "disproportionate'," said NHF deputy chief ... bear witness to the widespread and rising concern about the ...
... for the first ultrasound sight of the baby to be born in ... well and the pregnancy is on track. ,This is often ... day of the birth. However this is not enough for an increasing ... a clearer picture of their baby in the womb. ,The ...
Cached Medicine News:Health News:Doctors to give complete information on prescriptions to patients 2Health News:Doctors to give complete information on prescriptions to patients 3Health News:Vaccine for ear and sinus infections to be developed… 2Health News:Peek Before Birth 2
... ORTHOSET Radiopaque Bone Cement consists ... a sterile,ampule containing bone cement ... and a sterile polyethylene bag,containing ... peelable pouch. The interiors of ...
A "doughy" type of bone cement intended for manual application....
... Videoscopes provide superior image quality and ... the camera head with a C-mount ... more light at the operative site ... image clarity and reliability.,The Videoscopes have ...
... OMEGA 180 features a wide range of ... and Variable Pupil Control (U.S. Patent #4,684,227). ... down to 1.2mm. Heine's unique Diffuser aperture ... learning BIO easier, and simplifying difficult examinations. ...
Medicine Products: